ArticleBMC cancer2025
CD5 and p53 immunohistochemistry: valuable prediction method in molecular typing of CD5-positive diffuse large B-cell lymphoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD5 positive diffuse large B-cell lymphoma (DLBCL) has unique clinical and pathological characteristics.
methodsWe analyzed 25 cases of CD5-positive DLBCL, focusing on their clinical, morphological, immunohistochemical and genetic features.
resultsAmong the 13 females and 12 males, 14 were over 60 years (14/25, 56%). A majority of them presented in stage IV (15/21, 71.43%), primarily with extranodal lesions (14/25, 56%). The positive expression rates of CD20, CD10, BCL6, MUM1, MYC, and BCL2 were 100% (25/25), 40% (10/25), 84% (21/25), 100% (25/25), 87.5% (21/24) and 100% (25/25), respectively. Twenty-one cases (87.5%, 21/24) were MYC/BCL2 double-expressing. More than half of the cases were non-germinal center origin (15/25, 60%). The accuracy of p53 in predicting TP53 mutation was 95.65% (22/23). Genetic subtypes were MCD (13/25, 52%), TP53
conclusionsFor CD5 strong positive cases, a wild pattern of p53 likely indicates MCD subtype, while a mutant p53 pattern may suggest TP53
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.